Adjuvant Chemotherapy for Stage I Clear Cell Carcinoma of the Ovary

• DOI: 10.1097/igc.0b013e31823fd413
• Publication Date: 2012-03-07T12:43:15Z
• Authors: Toshio Takada; Haruko Iwase; Chiaki Iitsuka; Hidetaka Nomura; Kimihiko Sakamoto; Kohei Omatsu; Nobuhiro Takeshima; Ken Takizawa
• Keywords: Adjuvant Therapy

Although postoperative adjuvant chemotherapy is generally recommended for early-stage ovarian cancer, it remains unclear whether also effective clear cell carcinoma (CCC).Seventy-three patients with stage I CCC of the ovary who had undergone complete surgical staging formed study population (stage IA, 20 patients; IC, 53 patients). Survival and multivariate analyses were retrospectively performed to determine effectiveness in these patients.Of total (73 patients), 30 received C-positive), whereas 43 did not C-negative). The 5-year progression-free survival (PFS) overall (OS) rates C-positive group 80.1% 87.4% compared 73.9% 81.7% C-negative group. differences between groups significant (PFS: P = 0.610; OS: 0.557). Four IA underwent chemotherapy, remaining 16 no additional therapy. No recurrence was observed either Of IC CCC, 26 C-positive) 27 therapy There statistical difference PFS OS groups. without artificial rupture, 69.6% 34.6%, respectively, but 75.0% 70.0%, respectively (not significant). Multivariate confirmed that presence or absence a prognostic indicator.The current only fully staged patients, suggesting necessary patients. For suppressed recurrence, insufficient our limited study. Further studies are required clarify this.